A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration - Trial NCT06278766
Access comprehensive clinical trial information for NCT06278766 through Pure Global AI's free database. This Phase 1 trial is sponsored by AbbVie and is currently Recruiting. The study focuses on Healthy Volunteer. Target enrollment is 8 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
AbbVie
Timeline & Enrollment
Phase 1
Feb 21, 2024
Apr 19, 2024
Primary Outcome
Number of Participants with Adverse Events (AEs),Maximum observed concentration (Cmax) of ABBV-552,Time to Cmax (peak time, Tmax) of ABBV-552,Terminal phase elimination rate constant (ฮปz) of ABBV-552,Terminal phase elimination half-life (t1/2) of ABBV-552,Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration (AUCt) of ABBV-552,Area under the plasma concentration-time curve (AUC) from time 0 to infinite time (AUCinf) of ABBV-552,Amount of ABBV-552 excreted in the urine over the sampling period (Aeu),Percent of ABBV-552 excreted in the urine,Renal clearance ABBV-552 (CLr),Amount of ABBV-552 excreted in the feces over the sampling period (Aef),Percent radioactivity excreted in the feces
Summary
The purpose of this study is to evaluate mass balance, pharmacokinetics and safety of [14C]
 ABBV-552 in healthy, male volunteers following administration of a single oral dose.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06278766
Non-Device Trial